Prasugrel hydrochloride for the treatment of sickle cell disease

References

• Steinberg M. Overview of sickle cell anemia pathophysiology. In: Costa FF, Conran N, editors. Sickle cell anemia: from basic science to clinical practice. Switzerland: Springer International; 2016. p. 49–73.
   Google Scholar
• Costa FF, Fertrin KY. Clinical manifestations and treatment of adult sickle cell disease. In: Costa FF, Conran N, editors. Sickle cell anemia: from basic science to clinical practice. Switzerland: Springer International; 2016. p. 285–318.
   Google Scholar
• Brousse V, Buffet P, Rees D. The spleen and sickle cell disease: the sick(led) spleen. Br J Haematol. 2014;166:165–176.
   PubMed Web of Science ®Google Scholar
• Rees DC, Williams TN, Gladwin MT. Sickle-cell disease. Lancet. 2010;376:2018–2031.
   PubMed Web of Science ®Google Scholar
• Wun T, Brunson A. Sickle cell disease: an inherited thrombophilia. Am Soc Hematol Educ Program. 2016;2016:640–647.
   PubMedGoogle Scholar
• Noubouossie DC, Le PQ, Rozen L, et al. Thrombin generation in children with sickle cell disease: relationship with age, hemolysis, transcranial doppler velocity, and hydroxyurea treatment. Eur J Haematol. 2013;91:46–54.
   PubMed Web of Science ®Google Scholar
• Peters M, Plaat BE, Ten Cate H, et al. Enhanced thrombin generation in children with sickle cell disease. Thromb Haemost. 1994;71:169–172.
   PubMed Web of Science ®Google Scholar
• Stuart MJ, Setty BN. Hemostatic alterations in sickle cell disease: relationships to disease pathophysiology. Pediatr Pathol Mol Med. 2001;20:27–46.
   PubMed Web of Science ®Google Scholar
• Francis RB Jr. Elevated fibrin D-dimer fragment in sickle cell anemia: evidence for activation of coagulation during the steady state as well as in painful crisis. Haemostasis. 1989;19:105–111.
   PubMedGoogle Scholar
• Setty BN, Key NS, Rao AK, et al. Tissue factor-positive monocytes in children with sickle cell disease: correlation with biomarkers of haemolysis. Br J Haematol. 2012;157:370–380.
   PubMed Web of Science ®Google Scholar
• Shet AS, Aras O, Gupta K, et al. Sickle blood contains tissue factor-positive microparticles derived from endothelial cells and monocytes. Blood. 2003;102:2678–2683.
   PubMed Web of Science ®Google Scholar
• Key NS, Slungaard A, Dandelet L, et al. Whole blood tissue factor procoagulant activity is elevated in patients with sickle cell disease. Blood. 1998;91:4216–4223.
   PubMed Web of Science ®Google Scholar
• Solovey A, Kollander R, Shet A, et al. Endothelial cell expression of tissue factor in sickle mice is augmented by hypoxia/reoxygenation and inhibited by lovastatin. Blood. 2004;104:840–846.
   PubMed Web of Science ®Google Scholar
• Colella MP, De Paula EV, Machado-Neto JA, et al. Elevated hypercoagulability markers in hemoglobin SC disease. Haematologica. 2015;100:466–471.
   PubMed Web of Science ®Google Scholar
• Setty BN, Kulkarni S, Rao AK, et al. Fetal hemoglobin in sickle cell disease: relationship to erythrocyte phosphatidylserine exposure and coagulation activation. Blood. 2000;96:1119–1124.
   PubMed Web of Science ®Google Scholar
• Kenny MW, George AJ, Stuart J. Platelet hyperactivity in sickle-cell disease: a consequence of hyposplenism. J Clin Pathol. 1980;33:622–625.
   PubMed Web of Science ®Google Scholar
• Wun T, Paglieroni T, Rangaswami A, et al. Platelet activation in patients with sickle cell disease. Br J Haematol. 1998;100:741–749.
   PubMed Web of Science ®Google Scholar
• Proenca-Ferreira R, Franco-Penteado CF, Traina F, et al. Increased adhesive properties of platelets in sickle cell disease: roles for alphaIIb beta3-mediated ligand binding, diminished cAMP signalling and increased phosphodiesterase 3A activity. Br J Haematol. 2010;149:280–288.
   PubMed Web of Science ®Google Scholar
• Triadou P, Fonty E, Ambrosio AS, et al. Platelet function in sickle cell disease during steady state. Nouv Rev Fr Hematol. 1990;32:137–142.
   PubMedGoogle Scholar
• Mehta P, Mehta J. Abnormalities of platelet aggregation in sickle cell disease. J Pediatr. 1980;96:209–213.
   PubMed Web of Science ®Google Scholar
• Villagra J, Shiva S, Hunter LA, et al. Platelet activation in patients with sickle disease, hemolysis-associated pulmonary hypertension, and nitric oxide scavenging by cell-free hemoglobin. Blood. 2007;110:2166–2172.
   PubMed Web of Science ®Google Scholar
• Browne PV, Mosher DF, Steinberg MH, et al. Disturbance of plasma and platelet thrombospondin levels in sickle cell disease. Am J Hematol. 1996;51:296–301.
   PubMed Web of Science ®Google Scholar
• Novelli EM, Kato GJ, Ragni MV, et al. Plasma thrombospondin-1 is increased during acute sickle cell vaso-occlusive events and associated with acute chest syndrome, hydroxyurea therapy, and lower hemolytic rates. Am J Hematol. 2012;87:326–330.
   PubMed Web of Science ®Google Scholar
• Tomer A, Harker LA, Kasey S, et al. Thrombogenesis in sickle cell disease. J Lab Clin Med. 2001;137:398–407.
   PubMed Web of Science ®Google Scholar
• Zhang D, Xu C, Manwani D, et al. Neutrophils, platelets, and inflammatory pathways at the nexus of sickle cell disease pathophysiology. Blood. 2016;127:801–809.
   PubMed Web of Science ®Google Scholar
• Tomer A. Platelet activation as a marker for in vivo prothrombotic activity: detection by flow cytometry. J Biol Regul Homeost Agents. 2004;18:172–177.
   PubMed Web of Science ®Google Scholar
• Lee SP, Ataga KI, Orringer EP, et al. Biologically active CD40 ligand is elevated in sickle cell anemia: potential role for platelet-mediated inflammation. Arterioscler Thromb Vasc Biol. 2006;26:1626–1631.
   PubMed Web of Science ®Google Scholar
• Proenca-Ferreira R, Brugnerotto AF, Garrido VT, et al. Endothelial activation by platelets from sickle cell anemia patients. Plos One. 2014;9:e89012.
   PubMed Web of Science ®Google Scholar
• Garrido VT, Proenca-Ferreira R, Dominical VM, et al. Elevated plasma levels and platelet-associated expression of the pro-thrombotic and pro-inflammatory protein, TNFSF14 (LIGHT), in sickle cell disease. Br J Haematol. 2012;158:788–797.
   PubMed Web of Science ®Google Scholar
• Polanowska-Grabowska R, Wallace K, Field JJ, et al. P-selectin-mediated platelet-neutrophil aggregate formation activates neutrophils in mouse and human sickle cell disease. Arterioscler Thromb Vasc Biol. 2010;30:2392–2399.
   PubMed Web of Science ®Google Scholar
• Lee SP, Ataga KI, Zayed M, et al. Phase I study of eptifibatide in patients with sickle cell anaemia. Br J Haematol. 2007;139:612–620.
   PubMed Web of Science ®Google Scholar
• Dominical VM, Samsel L, Nichols JS, et al. Prominent role of platelets in the formation of circulating neutrophil-red cell heterocellular aggregates in sickle cell anemia. Haematologica. 2014;99:e214–7.
   PubMed Web of Science ®Google Scholar
• Wun T, Paglieroni T, Tablin F, et al. Platelet activation and platelet-erythrocyte aggregates in patients with sickle cell anemia. J Lab Clin Med. 1997;129:507–516.
   PubMed Web of Science ®Google Scholar
• Hidalgo A, Chang J, Jang JE, et al. Heterotypic interactions enabled by polarized neutrophil microdomains mediate thromboinflammatory injury. Nat Med. 2009;15:384–391.
   PubMed Web of Science ®Google Scholar
• Piel FB, Patil AP, Howes RE, et al. Global epidemiology of sickle haemoglobin in neonates: a contemporary geostatistical model-based map and population estimates. Lancet. 2013;381:142–151.
   PubMed Web of Science ®Google Scholar
• Piel FB, Williams TN. Sickle cell anemia: history and epidemiology. In: Costa FF, Conran N, editors. Sickle cell anemia: from basic science to clinical practice 1ed. Switzerland: Springer International; 2016. p. 23–47.
   Google Scholar
• Hassell KL. Population estimates of sickle cell disease in the U.S. Am J Prev Med. 2010;38:S512–21.
   PubMed Web of Science ®Google Scholar
• Murray CJ, Ezzati M, Flaxman AD, et al. GBD 2010: a multi-investigator collaboration for global comparative descriptive epidemiology. Lancet. 2012;380:2055–2058.
   PubMed Web of Science ®Google Scholar
• Shenoy S, Angelucci E, Arnold SD, et al. Current results and future research priorities in late effects after hematopoietic stem cell transplantation (HCT) for children with sickle cell disease and thalassemia: a consensus statement from the second pediatric blood and marrow transplant consortium international conference on late effects after pediatric HCT. Biol Blood Marrow Transplant. 2017;23:552–561.
   PubMed Web of Science ®Google Scholar
• Walters MC, De Castro LM, Sullivan KM, et al. Indications and results of HLA-identical sibling hematopoietic cell transplantation for sickle cell disease. Biol Blood Marrow Transplant. 2016;22:207–211.
   PubMed Web of Science ®Google Scholar
• Kwiatkowski JL, Cohen AR, Garro J, et al. Transfusional iron overload in children with sickle cell anemia on chronic transfusion therapy for secondary stroke prevention. Am J Hematol. 2012;87:221–223.
   PubMed Web of Science ®Google Scholar
• Petz LD, Calhoun L, Shulman IA, et al. The sickle cell hemolytic transfusion reaction syndrome. Transfusion. 1997;37:382–392.
   PubMed Web of Science ®Google Scholar
• Steinberg MH, Lu ZH, Barton FB, et al. Fetal hemoglobin in sickle cell anemia: determinants of response to hydroxyurea. Multicenter study of hydroxyurea. Blood. 1997;89:1078–1088.
   PubMed Web of Science ®Google Scholar
• Charache S, Barton FB, Moore RD, et al. Hydroxyurea and sickle cell anemia. Clinical utility of a myelosuppressive “switching” agent. The multicenter study of hydroxyurea in sickle cell anemia. Medicine (Baltimore). 1996;75:300–326.
   PubMed Web of Science ®Google Scholar
• Platt OS, Orkin SH, Dover G, et al. Hydroxyurea enhances fetal hemoglobin production in sickle cell anemia. J Clin Invest. 1984;74:652–656.
   PubMed Web of Science ®Google Scholar
• Ware RE, Davis BR, Schultz WH, et al. Hydroxycarbamide versus chronic transfusion for maintenance of transcranial doppler flow velocities in children with sickle cell anaemia-TCD with transfusions changing to hydroxyurea (TWiTCH): a multicentre, open-label, phase 3, non-inferiority trial. Lancet. 2016;387:661–670.
   PubMed Web of Science ®Google Scholar
• Telfer P, Bahal N, Lo A, et al. Management of the acute painful crisis in sickle cell disease- a re-evaluation of the use of opioids in adult patients. Br J Haematol. 2014;166:157–164.
   PubMed Web of Science ®Google Scholar
• Conran N. Prospects for early investigational therapies for sickle cell disease. Expert Opin Investig Drugs. 2015;24:595–602.
   PubMed Web of Science ®Google Scholar
• Nottage K, Estepp J, Hankins JS. Future perspectives for the treatment of sickle cell anemia. In: Costa FF, Conran N, editors. Sickle cell anemia: from basic science to clinical practice. Switzerland: Springer International; 2016. p. 399–429.
   Google Scholar
• Rosa GM, Bianco D, Valbusa A, et al. Pharmacokinetics and pharmacodynamics of ticagrelor in the treatment of cardiac ischemia. Expert Opin Drug Metab Toxicol. 2016;12:1491–1502.
   PubMed Web of Science ®Google Scholar
• Desai PC, Brittain JE, Jones SK, et al. A pilot study of eptifibatide for treatment of acute pain episodes in sickle cell disease. Thromb Res. 2013;132:341–345.
   PubMed Web of Science ®Google Scholar
• Ataga KI, Kutlar A, Kanter J, et al. Crizanlizumab for the prevention of pain crises in sickle cell disease. N Engl J Med. 2017;376:429–439.
   PubMed Web of Science ®Google Scholar
• Niitsu Y, Jakubowski JA, Sugidachi A, et al. Pharmacology of CS-747 (prasugrel, LY640315), a novel, potent antiplatelet agent with in vivo P2Y12 receptor antagonist activity. Semin Thromb Hemost. 2005;31:184–194.
   PubMed Web of Science ®Google Scholar
• Frelinger AL 3rd, Jakubowski JA, Brooks JK, et al. Platelet activation and inhibition in sickle cell disease (pains) study. Platelets. 2014;25:27–35.
   PubMed Web of Science ®Google Scholar
• Jakubowski JA, Zhou C, Small DS, et al. A phase 1 study of prasugrel in patients with sickle cell disease: pharmacokinetics and effects on ex vivo platelet reactivity. Br J Clin Pharmacol. 2013;75:1433–1444.
   PubMed Web of Science ®Google Scholar
• Styles L, Heiselman D, Heath LE, et al. Prasugrel in children with sickle cell disease: pharmacokinetic and pharmacodynamic data from an open-label, adaptive-design, dose-ranging study. J Pediatr Hematol Oncol. 2015;37:1–9.
   PubMed Web of Science ®Google Scholar
• Wun T, Soulieres D, Frelinger AL, et al. A double-blind, randomized, multicenter phase 2 study of prasugrel versus placebo in adult patients with sickle cell disease. J Hematol Oncol. 2013;6:17.
   PubMed Web of Science ®Google Scholar
• Heeney MM, Hoppe CC, Abboud MR, et al. A multinational trial of prasugrel for sickle cell vaso-occlusive events. N Engl J Med. 2016;374:625–635.
   PubMed Web of Science ®Google Scholar
• Co. ELa.. 2016. Effient [package insert]. [cited 2017 Feb 7]. Available from: https://pi.lilly.com/us/effient.pdf
   Google Scholar
• Braun OO, Johnell M, Varenhorst C, et al. Greater reduction of platelet activation markers and platelet-monocyte aggregates by prasugrel compared to clopidogrel in stable coronary artery disease. Thromb Haemost. 2008;100:626–633.
   PubMed Web of Science ®Google Scholar
• Payne CD, Li YG, Small DS, et al. Increased active metabolite formation explains the greater platelet inhibition with prasugrel compared to high-dose clopidogrel. J Cardiovasc Pharmacol. 2007;50:555–562.
   PubMed Web of Science ®Google Scholar
• Jakubowski JA, Winters KJ, Naganuma H, et al. Prasugrel: a novel thienopyridine antiplatelet agent. A review of preclinical and clinical studies and the mechanistic basis for its distinct antiplatelet profile. Cardiovasc Drug Rev. 2007;25:357–374.
   PubMed Web of Science ®Google Scholar
• Sugidachi A, Asai F, Ogawa T, et al. The in vivo pharmacological profile of CS-747, a novel antiplatelet agent with platelet ADP receptor antagonist properties. Br J Pharmacol. 2000;129:1439–1446.
   PubMed Web of Science ®Google Scholar
• Judge HM, Buckland RJ, Sugidachi A, et al. The active metabolite of prasugrel effectively blocks the platelet P2Y12 receptor and inhibits procoagulant and pro-inflammatory platelet responses. Platelets. 2008;19:125–133.
   PubMed Web of Science ®Google Scholar
• Jakubowski JA, Zhou C, Jurcevic S, et al. A phase 1 study of prasugrel in patients with sickle cell disease: effects on biomarkers of platelet activation and coagulation. Thromb Res. 2014;133:190–195.
   PubMed Web of Science ®Google Scholar
• Jakubowski JA, Payne CD, Brandt JT, et al. The platelet inhibitory effects and pharmacokinetics of prasugrel after administration of loading and maintenance doses in healthy subjects. J Cardiovasc Pharmacol. 2006;47:377–384.
   PubMed Web of Science ®Google Scholar
• Farid NA, Smith RL, Gillespie TA, et al. The disposition of prasugrel, a novel thienopyridine, in humans. Drug Metab Dispos. 2007;35:1096–1104.
   PubMed Web of Science ®Google Scholar
• Wrishko RE, Ernest CS 2nd, Small DS, et al. Population pharmacokinetic analyses to evaluate the influence of intrinsic and extrinsic factors on exposure of prasugrel active metabolite in TRITON-TIMI 38. J Clin Pharmacol. 2009;49:984–998.
   PubMed Web of Science ®Google Scholar
• Ohno K, Tanaka H, Samata N, et al. Platelet activation biomarkers in Berkeley sickle cell mice and the response to prasugrel. Thromb Res. 2014;134:889–894.
   PubMed Web of Science ®Google Scholar
• Jakubowski JA, Hoppe CC, Zhou C, et al. Real-time dose adjustment using point-of-care platelet reactivity testing in a double-blind study of prasugrel in children with sickle cell anaemia. Thromb Haemost. 2017;117:580–588.
   PubMed Web of Science ®Google Scholar
• Telen MJ, Wun T, McCavit TL, et al. Randomized phase 2 study of GMI-1070 in SCD: reduction in time to resolution of vaso-occlusive events and decreased opioid use. Blood. 2015;125:2656–2664.
   PubMed Web of Science ®Google Scholar
• Eaton WA, Bunn HF. Treating sickle cell disease by targeting HbS polymerization. Blood. 2017.
   PubMed Web of Science ®Google Scholar
• Nagalla S, Ballas SK. Drugs for preventing red blood cell dehydration in people with sickle cell disease. Cochrane Database Syst Rev. 2016;3:CD003426.
   PubMedGoogle Scholar
• Telen MJ. Beyond hydroxyurea: new and old drugs in the pipeline for sickle cell disease. Blood. 2016;127:810–819.
   PubMed Web of Science ®Google Scholar
• Tewari S, Brousse V, Piel FB, et al. Environmental determinants of severity in sickle cell disease. Haematologica. 2015;100:1108–1116.
   PubMed Web of Science ®Google Scholar